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OBJECTIVES: The proper nodal staging of non-small cell lung cancer is important for choosing the best treatment
modality. Although computed tomography remains the first-line imaging test for the primary staging of lung
cancer, its limitations for mediastinum nodal staging are well known. The aim of this study is to evaluate the
accuracy of hybrid single-photon emission computed tomography and computed tomography using
99mTc-sestamibi
in the nodal staging of patients with non-small cell lung cancer and to identify potential candidates for surgical
treatment.
METHODS: Prospective data were collected for 41 patients from December 2006 to February 2009. The patients
underwent chest computed tomography and single-photon emission computed tomography/computed tomogra-
phy examinations with
99mTc-sestamibi within a 30-day time period before surgery. Single-photon emission
computed tomography/computed tomography was considered positive when there was focal uptake of sestamibi in
the mediastinum, and computed tomography scan when there was lymph nodes larger than 10 mm in short axis.
The results of single-photon emission computed tomography and computed tomography were correlated with
pathology findings after surgery.
RESULTS: Single-photon emission computed tomography/computed tomography correctly identified six out of 19
cases involving hilar lymph nodes and one out of seven cases involving nodal metastases in the mediastinum. The
sensitivity, specificity, positive predictive value, and negative predictive value for
99mTc-sestamibi single-photon
emission computed tomography/computed tomography in the hilum assessment were 31.6%, 95.5%, 85.7%, and
61.8%, respectively. The same values for the mediastinum were 14.3%, 97.1%, 50%, and 84.6%, respectively. For the
hilar and mediastinal lymph nodes, chest tomography showed sensitivity values of 47.4% and 57.1%, specificity
values of 95.5% and 91.2%, positive predictive values of 90% and 57.1% and negative predictive values of 67.7%
and 91.2%, respectively.
CONCLUSION: Single-photon emission computed tomography/computed tomography with
99mTc-sestamibi showed
very low sensitivity and accuracy for the nodal staging of patients with non-small cell lung cancer, despite its high
level of specificity. In addition, the performance of single-photon emission computed tomography/computed
tomography added no relevant information compared to computed tomography that would justify its use in the
routine preoperative staging of non-small cell lung carcinoma.
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INTRODUCTION
The survival of lung cancer patients is related to the
extent of their disease at the time of diagnosis. In the
absence of distant metastases, the spread of tumors to the
mediastinal lymph nodes is a major determinant of both the
prognosis and the therapeutic approach. Proper staging is
important for selecting patients who may benefit from
surgical resection and for defining the treatment modalities
of patients who will undergo radiotherapy.
The histopathologic evaluation of lymph nodes is consid-
ered the gold standard in assessing the presence or absence of
metastases in the mediastinum. There are several invasive
methods that can be used for this purpose: mediastinoscopy,
anterior mediastinotomy, transthoracic needle aspiration,
endobronchial or esophageal ultrasound with needle aspira-
tion, and thorachoscopy.
1,2 Mediastinoscopy is the most
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1901common invasive test. It has a mean sensitivity of up to 80%,
with a range of 44% to 97%. With this method, only high and
low paratracheal, pre-tracheal, and subcarinal lymph nodes
are accessible; there is also a low but real risk of morbidity
and mortality.
1
In an attempt to reduce the frequency of invasive methods
or to guide the most appropriate procedures for lymph node
biopsies, noninvasive imaging tests are used when applic-
able. Computed tomography (CT) is the imaging method of
choice in the evaluation and staging of primary cancers. The
diagnosticCTcriteria fortheinvolvement oflymphnodesare
based on their sizes, especially when their minor axes are
longer than ten millimeters. However, small lymph nodes
that are considered normal according to such criteria may
contain tumor cells, while inflammatory and infectious
diseases may be responsible for enlarged lymph nodes,
limiting the overall effectiveness of this diagnostic test. In a
meta-analysis by Toloza that evaluated 20 studies, chest CT
examinations showed a sensitivity of 57%, specificity of 82%,
and positive and negative predictive values of 56% and 83%,
respectively.
3
Tomographic imaging in nuclear medicine is based on the
metabolic activity of tissues and may be useful for
identifying pathological changes before they are detected
by radiological examinations such as CTs. PET (positron
emission tomography) scans with
18F-FDG (
18F-fluorodeox-
yglucose) have superior sensitivity and specificity com-
pared to chest CTs and are considered the most accurate
imaging method for staging patients with lung cancers.
3-5
However, there are limitations related to positive predictive
value of this method because there may be FDG uptake in
inflammatory cells.
6 The sensitivity can also be decreased
when lymph node metastasis is microscopic or below the
spatial resolution threshold of current, state-of-the-art
scanners.
7 In Brazil, the availability of PET is restricted to
a few institutions because of equipment costs and avail-
ability of comercial doses of FDG regarding the number of
cyclotrons installed in Brazil.
Alternatively, single-photon emission computed tomo-
graphy (SPECT) is widely available, has lower costs than
PET, and does not require the presence of a cyclotron
adjacent to the hospital. Sestamibi (hexakis-2-methoxyiso-
butyl-isonitrile) labeled with technetium (
99mTc-sestamibi)
is a lipophilic cation that is routinely used in myocardial
perfusion imaging and has been used as a tumor-seeking
agent.
8
Encouraging results have been obtained with SPECT
scanning using sestamibi to detect primary lung malignan-
cies
9-11 and to perform mediastinal staging with a higher
diagnostic accuracy higher than chest CTs.
12,13
Despite the positive results obtained with sestamibi,
particularly regarding its specificity, there are difficulties
in the analysis of mediastinal images. The main difficulty
is related to the limited spatial resolution of SPECT.
Furthermore, the vascular structures in the mediastinum
and heart, where sestamibi is taken up, interfere with the
correct interpretation of the images and could cause false
positive results and decrease the diagnostic capability of the
method.
The association of functional images and anatomical
information from CTs may be useful in interpreting
SPECT by providing more accurate data regarding the
location and extent of tumor lesions. Hybrid devices usually
have dual detectors, with scintillation cameras and low-dose
CT scanners. Sequentially, data from both CT and SPECT
are acquired. The two images are merged, creating SPECT
images that are superimposed on corresponding anatomical
planes. This image fusion may help to differentiate between
tumors and other areas of physiological activity.
14,15
The aim of this study is to evaluate the accuracy of
SPECT/CT using the radiotracer
99mTc-sestamibi in the
mediastinal lymph node staging of patients with non-small
cell lung cancer and candidates to surgical treatment.
MATERIALS AND METHODS
Patients
A cross-sectional study with prospective data collection
was conducted from December 2006 to February 2009 at the
Hospital de Ca ˆncer de Barretos-SP. The study was approved
by the Institutional Ethics Committee. The inclusion criteria
were as follows: 1) patients of either sex, 2) patients who
were at least 18 years old, 3) patients with histological
diagnoses of non-small cell lung cancer (e.g., squamous cell
carcinoma, adenocarcinoma or large cell carcinoma) or
pulmonary lesions that were strongly suspicious for
neoplasia, 4) patients with clinical stages I, II, or III, as
classified by the sixth edition of TNM
16 with performance
status that allowed surgery enrollment (ECOG PS zero or 1),
and 5) patients who agreed to participate in the study and
signed the informed consent form. Patients were excluded if
their diagnosis of non-small cell lung cancer was not
confirmed after surgical resection. Patients with bulky
lymph node metastases that were considered unresectable
and pregnant patients were also excluded.
The clinical evaluation included: physical examination,
hematologic and biochemic screening, cardiologic evalua-
tion, bronchoscopy when the pulmonary lesions were
considered accessible for this method, bone scan, chest
and upper abdomen CT, brain MRI or CT. Forty one
patients were enrolled in the study. All of the patients were
submitted to surgical procedures for diagnosis and treat-
ment which were performed within 30 days after chest CT
and SPECT/CT. The type of resection performed on each
patient was defined by the thoracic surgery team in
accordance with the extent of the primary tumor.
Mediastinal systematic lymph node dissection was per-
formed for adequate pathological staging according to the
tumor location. For tumors of the right lung, a mediastinal
dissection included the ipsilateral hilar region as well as the
upper and lower paratracheal, subcarinal and paraesopha-
geal lymph nodes. For left lung tumors, the left hilar region,
lower paratracheal area, aortopulmonary window, and
para-aortic, subcarinal, and paraesophageal lymph nodes
were sampled. Lymph nodes were identified according to
the Mountain nodal station classification system
16 and were
sent for histopathological analysis, which was performed by
an experienced pathologist with expertise in lung cancer.
The largest diameter of the metastatic foci in the lymph
nodes was divided into two groups: those ,10 mm and
those $10 mm.
99mTc-sestamibi SPECT/CT
The GE Medical Systems, Millennium VG, Hawkeye
hybrid equipment was used. Every patient received an
injection of 1,110 MBq (30 mCi) of
99mTc-sestamibi, which
was prepared following the manufacturer’s instructions
(Bristol-Myers Squibb Medical Imaging, Massachusetts,
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1902USA). Images were acquired 10 minutes after the adminis-
tration of sestamibi with patients placed in supine positions
with their arms elevated.
SPECT: Emission images were acquired using a dual-head,
large field-of-view scintillation camera equipped with a low-
energy, high-resolution collimator (VPC-45). The images
were acquired every 20 seconds, at a 3˚ angle, in a circular
orbit of 180˚per detector array, and using a 1286128 matrix.
The equipment was calibrated for a photopeak of 140 keV
with a symmetric 20% window.
CT images were acquired sequentially in a non-dedicated
3rd-generation scanner installed in the SPECT camera
gantry, with a 10 mm slice thickness (maximum of 40
slices), a maximum current of 2.5 mA and a 140 kV
potential.
The raw data from SPECT and CT were transferred from
the acquisition equipment to an Entegra workstation
(General Electric Healthcare), and the tools provided by
the manufacturer were used to process the data. The
following iterative processing protocol in standard 2-D
was used. The image reconstruction was made after
automatic pre-processing, which included the reconstruc-
tion of the SPECT plane imaging, the reformatting of the
anatomical and functional sections according to the type of
organ and the creation of maximum-intensity projection
imaging. The Butterworth filter was used with a cutoff
frequency of 0.28 Nyquist and an order of 10. After this
initial step, the images were reoriented to obtain transaxial,
coronal, and sagittal views.
All images were independently interpreted by two
nuclear physicians who were blinded to the chest CT and
pathology findings. Disagreements in the analysis were
resolved by consensus.
The following aspects were analyzed regarding the
primary pulmonary lesion: 1) presence or absence of
sestamibi uptake; 2) qualitative visual assessment of
sestamibi uptake, which was classified as mild, moderate
or intense. As a parameter, the uptake in primary tumor was
compared with uptake in physiological thoracic structures
as follows: more than soft tissues (mild) and less than
hepatic uptake; similar to hepatic uptake (moderate); similar
to cardiac uptake (intense). The intensity of uptake was
correlated with histology and tumor size. 3) a semi-
quantitative analysis obtained by outlining the regions of
interest (ROI) over the tumor (T) and in the contralateral
normal lung (L). ROI was defined manually on coronal
images that showed the tumors’ highest degree of uptake.
The maximum ROI values were measured, and the TL/T
index was calculated. This analysis was correlated with the
histology, tumor size and tumor size was analyzed as a
continuous variable and also divided into three categories:
1) less than or equal to 3.0 cm, 2) greater than 3.0 cm and
less than or equal to 7.0 cm and 3) greater than 7.0 cm.
With regard to the lymph nodes, the following aspects
were analyzed: 1) the presence or absence of focal uptake in
the mediastinum or hilum; 2) a qualitative visual assess-
ment of the sestamibi uptake, which was classified as mild,
moderate or intense; 3) a semi-quantitative analysis that was
performed in the same manner as the analysis conducted for
the primary lesion, comparing radiotracer uptake in the
lymph nodes and the lung; and 4) the identification of
uptake lymph node chains in accordance with the interna-
tional system adopted by the American Joint Committee on
Cancer (AJCC) and the International Union Against Cancer
(UICC), which is the classification proposed by the
American Thoracic Society and modified by Mountain-
Dresler (MD-ATS).
17
Chest CT
All CT scans were performed on a Hispeed CT (GE,
Milwaukee) after intravenous administration of an iodi-
nated contrast agent at a dose of 1.0 ml/kg. Helical CT scans
were performed with a slice thickness of 7 mm, pitch of 1.5
and reconstruction thickness of 5 mm. The scans had a
window for the lung parenchyma and a window for the
mediastinum and were acquired from the lower cervical
region to the upper lumbar region, including the adrenal
glands.
The images were read independently by two radiologists
who were blinded to the SPECT and pathological findings.
Disagreements in the assessments were resolved by con-
sensus. In the axial plane, those lymph nodes larger than
10 mm on their smallest axis were considered suspicious
for metastasis. The lymph node stations were identified
according to the international system adopted by the AJCC
and the UICC.
17
Statistical analysis
To calculate the diagnostic efficacy as determined by the
sensitivity, specificity, positive predictive value and nega-
tive predictive value, the SPECT/CT results were compared
to pathology analyses, which were defined as the reference
test. The same assessment was conducted to evaluate the
accuracy of chest CTs. A descriptive analysis was performed
by measuring the central tendency, dispersion, and relative
frequencies of patient and tumor characteristics.
The inter-observer agreement was calculated by the
Kappa index. In the analysis of the correlation between
numerical variables, a Spearman’s correlation coefficient
test was used. The chi-square test was used to assess the
relationships between categorical variables. Kruskal-Wallis
and Mann-Whitney nonparametric tests were used to
evaluate the relationships between continuous and catego-
rical variables. The level of significance was set at 0.05.
All statistical analyses were performed with the SPSS
(version 18.0) software package.
RESULTS
From December 2006 to February 2009, 46 patients with
potentially resectable lung lesions were included in our
study. Among these patients, five were excluded for the
following reasons. In one patient, the pathological results
revealed a carcinoid tumor. For another patient, a chest CT
was not performed at our institution. In three other cases,
SPECT evaluations were not performed.
The characteristics of the 41 patients that were included in
this study are summarized in Table 1. Two lesions, a
squamous cell carcinoma, and an adenocarcinoma, were
diagnosed in one patient. Therefore, we analyzed a total of
42 primary lung lesions in 41 patients.
Primary tumor
Primary tumor: SPECT/CT. We found evidence of
radiotracer uptake in 39 out of 42 pulmonary lesions
(92.8%). Thirty-one lesions were classified as mild in
intensity, and eight lesions were classified as moderate in
intensity. In three patients (7.2%), the primary tumor did not
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1903concentrate sestamibi. The mean size of these lesions was
1.9 cm. For those tumors that concentrated sestamibi, the
mean size was 5.0 cm. Although the mean size of those
lesions that showed sestamibi uptake was significantly
higher than the mean size of those lesions that did not
(p=0.009), no statistically significant differences between
the intensity of uptake (mild or moderate) and the tumor
size (p=0.8) or between the degree of uptake and the tumor
histological type (p=0.2) were found.
Regarding the quantitative analysis, the rate of uptake in
primary tumors ranged from 0.17 to 0.76 (average of 0.50).
T h e r ew a sn oc o r r e l a t i o nb e t w e e nt h er a t eo fu p t a k ea n dt h e
tumor size (correlation coefficient=0.081, p=0.6). Further-
more, there was no statistically significant difference between
t h er a t eofu pt a k ea n dp r i m a r yt u m o rl e s i o n st h a twe r es m a l l e r
than or equal to 3.0 cm, greater than 3.0 cm and less than or
equalto7.0 cmorgreaterthan 7.0 cm(p=0.8). The histological
type did not influence the rate of uptake (p=0.55).
Lymph Nodes
The mean number of resected hilar and mediastinal
lymph nodes and the number of patients with hilar and
mediastinal metastases by pathology examination, which
was considered to be the reference method, are described
in Table 1. Of the seven patients with metastases in the
mediastinal lymph nodes, six also had metastases in the
hilum. There was only one case of metastasis in the
mediastinum with no involvement of the hilar lymph nodes
(skip metastasis). The metastatic foci were smaller than
10 mm in 12 out of 19 patients (63.1%) with metastases of
the hilar lymph nodes and in three out of the seven patients
(42.9%) with mediastinal lymph node metastases.
With regard to the pathological staging of the lymph
nodes, 21 patients (51.3%) had no regional metastases and
were therefore classified by the TNM system as pN0.
Thirteen (31.7%) had metastases only in the hilar lymph
nodes and were staged as pN1, and seven patients (17%)
were classified as pN2 because they had metastases in the
mediastinal lymph nodes.
Lymph nodes: SPECT/CT and CT
SPECT/CT with sestamibi correctly identified six out of
19 cases with involvement of the hilar lymph nodes
(Figure 1). In four of these cases, the metastatic foci were
larger than or equal to 10 mm. In two cases, the foci were
smaller than 10 mm. In ten out of 13 cases in which SPECT
was falsely negative, the metastases were smaller than
10 mm (i.e., below the spatial resolution threshold of
SPECT).
In 22 cases, there was no involvement of the hilar lymph
nodes by pathology examination, and sestamibi correctly
staged 21 of these cases. Therefore, there was one false
positive result where the analysis of this lymph node
showed a reactive process, with the presence of sinus
histiocytosis and follicular hyperplasia.
Regarding mediastinum staging by SPECT/CT, the
method correctly evaluated only one out of seven patients
with nodal metastases, as confirmed by pathology examina-
tions. The positive node in this case was located on the
aorto-pulmonary window, and the metastasis was larger
than 10 mm (Figure 2). In the six false negative cases, the
sizes of the lymph node metastases were smaller than
10 mm in three cases and larger than 10 mm in three other
cases. SPECT/CT made a correct diagnosis in 33 out of 34
patients without lymph node involvement, as confirmed by
pathology examinations. Therefore, there was one false
positive result, which occurred in the same patient in which
there was a false positive finding in the hilum.
The degree of uptake was considered to be mild in all
cases. The mediastinal lymph node uptake index was 0.14
and ranged from 0.2 to 0.47 for the hilar lymph nodes.
CT provided the correct diagnosis in nine out of 19 cases
with metastasis of the hilum. Of the 22 patients without
lymph node involvement, CT was negative in 21 patients.
Regarding the mediastinum, CT correctly assessed four out
of seven cases with nodal metastases and 31 out of 34
patients without lymph node involvement.
The sensitivity, specificity, positive predictive value, and
negative predictive value of SPECT/CT and CT in the
analyses of the hilar and mediastinal lymph nodes are
described in Table 2.
Table 3 describes the locations and sizes of the primary
tumors, histology, chains with positive nodes, sizes of
lymph node metastases, and diagnoses of the two imaging
methods (SPECT/CT and CT) for the seven patients with
positive lymph nodes in the mediastinum.
The reproducibility analysis of the imaging method in
relation to the pathology results revealed regular kappa
values for CT in the analysis of the mediastinum (0.5) and
the hilum (0.4) and a weak agreement for SPECT/CT for the
mediastinum (Kappa 0.1) and the hilum (Kappa 0.3).
Between the two observers who evaluated the SPECT/CT
results, there was complete diagnostic agreement in all 41
cases for the evaluation of the mediastinum (Kappa 1) and
disagreement in two cases for the hilum analysis (kappa
0.8). For the CT images, the diagnosis differed in only one
Table 1 - Patient characteristics (n=41).
Age (years), range (mean) 45-78 (62.6)
Gender (male/female) 28 (68.3%)/13 (31.7%)
Histopathology diagnosis
Thoracotomy
Fine-needle aspiration
Bronchoscopy
24 (58.5%)
11 (26.8%)
6 (14.6%)
Histology
Adenocarcinoma
Squamous cell carcinoma
Broncholoalveolar
Adenosquamous
Non-small cell carcinoma
22 (52.2%)
13 (31%)
5 (12%)
1 (2.4%)
1 (2.4%)
Primary tumor size (cm), range (mean) 1.5-11.5 (4.7)
Tumor classification (TNM)
T1
T2
T3
T4
9 (21.4%)
23 (54.8%)
9 (21.4%)
1 (2.4%)
Lesion size
Range (mean) without sestamibi uptake (cm)
Range (mean) with sestamibi uptake (cm)
1.5-2.5 (1.9)
2.0-11.5 (5.0)
Number of resected hilar lymph nodes 2-28 (10.3)
Number of resected mediastinal lymph 4-44 (22.3)
Hilar metastasis 19 (46.3%)
Mediastinal metastasis 7 (17.7%)
Size of metastatic foci
Hilar lymph nodes
,10 mm
$10 mm
Mediastinal lymph nodes
,10 mm
$10 mm
12 (63.1%)
7 (36.9%)
3 (42.9%)
4 (57.1%)
Lung cancer nodal staging with SPECT/CT
Miziara JM et al.
CLINICS 2011;66(11):1901-1909
1904case in the assessment of the hilum (Kappa 0.9) and in two
cases in the assessment of the mediastinum (Kappa 0.8).
DISCUSSION
Chest CT is the most commonly performed imaging test
for the primary staging of lung cancers. However, it has low
sensitivity and may compromise the selection of treatment
options for patients. Currently, the sizes of the lymph nodes
are the main radiological criteria used to classify lymph
nodes as suspicious for metastatic disease; they are usually
considered positive when the short axis diameter is larger
than 10 mm. However, lymph nodes of a normal size may
contain tumor cells and thus lead to false negative results
and low sensitivity. With chest CTs, our study found a
sensitivity of 57% in the evaluation of the mediastinum,
which was similar to the sensitivity described in other
studies.
3,18 For the hilar lymph nodes, the sensitivity of CT
Figure 1 - SPECT/CT showing left hilar sestamibi uptake in a patient with an adenocarcinoma of the left lung.
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1905was 47.4%, which was lower than the mediastinal CT
sensitivity.
In a prospective study that assessed the role of chest CT in
the preoperative staging of 49 patients with non-small cell
lung cancer, the hilar CT sensitivity was only 11%, which
was lower than the sensitivity of 67% found for mediastinal
lymph nodes.
19 Perhaps this difference is due to the greater
difficulty in evaluating the hilar region using this method
than in evaluating other regions. In our study, CT specificity
was higher than 90% for both the pulmonary hilum and the
mediastinum. Such a high specificity might be related to the
study population, which included only patients who were
being considered for surgical treatment and who therefore
had no bulky adenopathies. Toloza et al. found a mean
specificity of 82% (ranging from 57% to 93%) in their meta-
analysis. Moreover, the accuracy of chest CTs in the staging
Figure 2 - SPECT/CT showing aorto-pulmonary window (station five) uptake in a patient with an adenocarcinoma of the left lung.
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1906of the mediastinum was not superior to that found in earlier
meta-analyses, suggesting that despite the superior resolu-
tion of most modern scanners, CTs did not lead to better
accuracy for nodal staging.
3
However, in a recent retrospective study that evaluated
the accuracy of multi-slice chest CTs in mediastinum nodal
staging in 86 patients with non-small cell lung cancer, the
sensitivity, specificity, positive and negative predictive
values, and accuracy were 100%, 98.5%, 94.4%, 100%, and
98.8%, respectively. For its diagnostic criteria, this study
used not only lymph node size but also the locations of the
lymph nodes in relation to the position of the primary tumor
and the lymph node structure. For example, the presence of
central calcification and fat density were used as common
signs of negative or normal nodes. Peripheral calcifications
and necrosis were also considered as positive findings.
When only the sizes of the lymph nodes (short axis larger
than 10 mm) were considered, the effectiveness of the test
was decreased, with sensitivity, specificity, positive and
negative predictive values and accuracy values of 64%, 61%,
87%, 40%, and 62%, respectively. These findings suggest
that when factors other than size are also considered, the
diagnostic efficacy of multi-slice CTs can be enhanced.
20
Although PET results have been shown to be superior to
chest CTs in the evaluation of regional lymph nodes, and
although the association between PET and CT (PET/CT)
seems to be more effective in staging the mediastinum than
simply relying on PET imaging,
4-6 PET/CT was not
available in our institution. The rationale for performing
this study was based on the scarce and controversial
evidence regarding the value of SPECT/CT with sestamibi
in staging lung cancers, especially considering its higher
availability and lower costs compared to PET.
9-13
SPECT/CT showed mild or moderate sestamibi uptake in
39 out of 42 pulmonary lesions (92.85%). Only three lesions
did not concentrate sestamibi, and these lesions were the
smallest tumors in the sample. However, the mean size of
the lesions that showed no uptake was 1.9 cm, which is
considered to be within the diagnostic power of modern
SPECT scanners.
In 31 cases, the degree of uptake was mild according to
the criteria adopted in the study (i.e., lower than the degree
of uptake in the liver and higher than the degree of uptake
in soft tissues). In eight cases, the degree of uptake was
similar to the degree of liver uptake and was therefore
considered moderate. Although the degree of uptake was
considered mild for most lesions, it was much higher than
the degree of uptake seen in soft tissues. It is possible that
the comparison criteria that were selected in an attempt to
make the interpretation more objective were not adequate
because we observed that the degree of liver uptake was
very similar to the degree of heart uptake, which can be
considered intense in these two organs. In contrast to the
findings reported with FDG-PET in lung cancer, our study
did not show any direct correlation between the degree of
sestamibi uptake in primary lesions and lymph nodes and
the size and histology classification of tumors. That means,
larger lesions or more agressive histology types of tumors
were not associated with higher sestamibi uptake. One
potential explanation is a difference in the transmembrane
electrical potential, while another is the degree of neovas-
cularity. Although aggressive histologies should show
higher levels of sestamibi uptake, this phenomenon was
not observed in our study sample. The size of the tumor is
important because larger tumors are more easily detected
by SPECT imaging. However, larger tumors have larger
necrotic areas. In addition, necrotic, fibrotic and/or inflam-
matory tissues were not quantified by the pathology
examinations in our study, and no corrective measurements
were taken according to the histology findings.
In a study evaluating 25 patients with indeterminate
pulmonary nodules, Minai et al. found a sensitivity of 85.7%
and a specificity of 100% for sestamibi SPECT. Two of the
three false negative cases occurred with the smallest
nodules in the study, which had sizes ranging from 1.2 to
Table 2 - SPECT/CT and CT results for the analyses of the
hilar and mediastinal lymph nodes.
Test Sensitivity Specificity PPV NPV
SPECT/CT (hilum) 31.6% 95.5% 85.7% 61.8%
CT (hilum) 47.4% 95.5% 90% 67.7%
SPECT/CT
(mediastinum)
14.3% 97.1% 50% 84.6%
CT
(mediastinum)
57.1% 91.2% 57.1% 91.2%
Note: PPV: positive predictive value; NPV: negative predictive value.
Table 3 - Patients with mediastinal lymph node metastasis (n=7).
Patient
Primary tumor
localization
Size of primary
tumor (cm) Histology
Positive lymph
node stations Metastasis size SPECT TC
2 SRL 2.7 Adenocarcinoma 2
3
4R
,10 mm
,10 mm
$10 mm
-
-
-
-
-
-
3 ILL 4.5 Adenocarcinoma 7 ,10 mm - +1.7 cm
8 ILL 11.5 Adenocarcinoma 5
8
$10 mm
,10 mm
+
-
+1.2 cm
-
11 ILL 7.0 Adenocarcinoma 7
8
$10 mm
$10 mm
-
-
-
-
13 IRL 2.4 Adenocarcinoma 4R
7
8
,10 mm
,10 mm
$10 mm
-
-
-
-
-
-
22 SLL 11.0 Adenocarcinoma 4L
5
6
,10 mm
,10 mm
,10 mm
-
-
-
-
+ 1.1 cm
-
31 SLL 7.5 SCC 5 ,10 mm - +1.2 cm
Note: SRL superior right lobe; ILL inferior left lobe; IRL inferior right lobe; SLL superior left lobe.
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9 Santini et al. also studied the role of sestamibi in the
diagnosis of pulmonary lesions. There was sestamibi uptake
in 91.6% of the malignant lesions, while only 8.3% of the
identified tumors showed no sestamibi uptake.
11 These
results are consistent with the results of our study.
SPECT/CT with sestamibi correctly identified six of 19
cases with involvement of the hilar lymph nodes, with a
sensitivity of 31.6%. Only one out of seven patients with
mediastinal nodal metastases, identified by pathology
examinations, were correctly identified, leading to a
sensitivity of only 14.3%. SPECT/CT sensitivity values for
both the hilum and the mediastinum were inferior to the
sensitivity of chest CT; these values were also lower than the
sensitivity values described in previous studies. One
hypothesis is that the sizes of the metastases in the lymph
nodes were smaller than the sizes reported in previous
studies. In the 13 cases in which SPECT have a false negative
result for the hilum, the majority of metastases were smaller
than 10 mm (n=10; 76.9%). In the mediastinum, 50% of the
lymph nodes were smaller than 10 mm.
Regarding mediastinal nodal staging by sestamibi SPECT,
Chiti et al. evaluated 36 patients with pulmonary lesions
and showed a higher accuracy for SPECT than for chest CT.
SPECT correctly staged 10 out of 11 patients with
mediastinal metastases and 21 out of 25 without mediastinal
metastases, with sensitivity and specificity values of 91%
and 84%, respectively. However, node enlargement was
seen by CT in the majority of the patients with confirmed
nodal involvement (80%), in contrast to our findings.
12
Nosotti et al. studied 87 patients with non-small cell lung
cancer and found a sensitivity of 54.5% and a specificity of
100% for sestamibi SPECT in the analysis of nodal staging.
The lymph nodes were evaluated by mediastinoscopy or
thoracotomy; however, the numbers and sizes of the lymph
nodes that were resected were not described in detail.
13
In a prospective study evaluating the value of PET/CT in
the nodal staging of 51 patients with lung cancers who were
scheduled for surgery, the sensitivity was as low as 40%,
mainly because of the small sizes of the lymph nodes
(,10 mm).
7
The sensitivity of PET/CT in the preoperative staging
of regional thoracic lymph nodes was 54.2% in a study
involving 159 patients with resectable lung cancers. The
specificity was 91.9%. The mean size of the lymph nodes
that were falsely negative on PET/CT was 7.8 mm, with a
minimum size of 3 mm and a maximum size of 15 mm. The
method correctly identified 85.3% of the lymph nodes that
were larger than 10 mm and 32.4% of the patients with
lymph node metastases that were smaller than 10 mm. The
authors concluded that the spatial resolution of PET/CT
appears to be inadequate to detect lymph node metastases
that are smaller than 10 mm.
21 This finding is also more
relevant for SPECT that has lower spatial resolution than
PET.
Although the hybrid system used in the present study
had an attached CT with a much lower resolution than a
multidetector CT, the method was effective in excluding the
areas of physiological uptake and possibly decreasing the
rate of false positive results. There was only one false
positive result, which was represented by an inflammatory
reaction in the affected lymph node and found through a
pathology examination.
Previous studies have shown that the fusion of SPECT
and CT can help to differentiate tumor activity and
physiological activity.
15 The main advantage of SPECT/CT
in our study was the ability to distinguish areas of tumor
uptake from those of cardiac and/or vascular uptake,
helping to reduce the frequency of false positive results
while simultaneously providing higher specificity (.95%).
Despite the limited resolution of SPECT, which made it
difficult to interpret the results due to low sensitivity and
many false negative results, the strong agreement between
observers in the analysis of the mediastinum and the hilum
should be noted. This agreement suggests that image
interpretation was consistent between experts and that the
poor results were likely due to the limitations of the method.
In conclusion, SPECT/CT using
99mTc-sestamibi seems to
play no role in the nodal staging of patients with non-small
cell lung carcinoma because the technique is associated with
a much lower sensitivity than CT or pathology analyses.
Moreover, no incremental diagnostic value of SPECT could
be observed in the present study, especially when compared
to the staging information provided by chest CT. However,
more studies are needed that use devices equipped with
multidetector CT scanners, which could provide more
accurate registration and simultaneously offer more ade-
quate attenuation corrections for emission scans.
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